{"id":"low-dose-capecitabine","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Hand-foot syndrome"},{"rate":"20-50%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells. The inhibition of thymidylate synthase also reduces the production of thymidine, a nucleotide required for DNA synthesis.","oneSentence":"Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:33.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of Dukes' C and D colon cancer"},{"name":"Monotherapy for treatment of advanced colorectal cancer"},{"name":"Adjuvant treatment of stage III (Dukes' C) colon cancer"},{"name":"Monotherapy for treatment of metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT06926868","phase":"PHASE2, PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":"Breast Neoplasms","enrollment":500},{"nctId":"NCT07483060","phase":"PHASE4","title":"Next Generation STAR-TREC (NG-ST) - Organ Preservation in Early Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2026-03-12","conditions":"Rectal Cancer","enrollment":90},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT06018337","phase":"PHASE3","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-01-18","conditions":"Metastatic Breast Cancer","enrollment":541},{"nctId":"NCT07448142","phase":"PHASE2","title":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-15","conditions":"Colorectal Cancer (CRC)","enrollment":50},{"nctId":"NCT02669173","phase":"PHASE1","title":"Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2016-10-11","conditions":"Glioblastoma","enrollment":12},{"nctId":"NCT07408609","phase":"PHASE2","title":"Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-26","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":114},{"nctId":"NCT07397442","phase":"PHASE2","title":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-03-01","conditions":"Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":19},{"nctId":"NCT07347951","phase":"PHASE2","title":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-12-01","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":30},{"nctId":"NCT04095299","phase":"PHASE3","title":"Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients","status":"RECRUITING","sponsor":"Vejle Hospital","startDate":"2020-01-20","conditions":"Cancer of Rectum","enrollment":162},{"nctId":"NCT06105684","phase":"PHASE2","title":"Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-02-14","conditions":"Metastatic Breast Cancer","enrollment":40},{"nctId":"NCT07068763","phase":"PHASE2","title":"Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-10-09","conditions":"Rectal Cancer","enrollment":52},{"nctId":"NCT04556773","phase":"PHASE1","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-17","conditions":"Metastatic Breast Cancer","enrollment":138},{"nctId":"NCT07268677","phase":"PHASE2","title":"A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.","status":"NOT_YET_RECRUITING","sponsor":"Guoxiang Cai","startDate":"2025-12-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT04753879","phase":"PHASE2","title":"Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-09-29","conditions":"Metastatic Pancreatic Cancer","enrollment":38},{"nctId":"NCT04443348","phase":"PHASE2","title":"Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laura M. Spring, MD","startDate":"2020-12-16","conditions":"Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)","enrollment":120},{"nctId":"NCT05840211","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-08","conditions":"Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":654},{"nctId":"NCT05609370","phase":"PHASE1, PHASE2","title":"A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-29","conditions":"Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer","enrollment":113},{"nctId":"NCT05980481","phase":"PHASE2, PHASE3","title":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-08-04","conditions":"Gastric Cancer","enrollment":201},{"nctId":"NCT06124378","phase":"PHASE2","title":"Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2023-11-13","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":60},{"nctId":"NCT07143097","phase":"PHASE2","title":"Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2021-11-01","conditions":"Triple -Negative Breast Cancer","enrollment":80},{"nctId":"NCT07132008","phase":"PHASE3","title":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2025-10-01","conditions":"Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors","enrollment":94},{"nctId":"NCT07132463","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Rectal Cancer","enrollment":154},{"nctId":"NCT07070622","phase":"PHASE3","title":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-11-01","conditions":"Rectal Cancer","enrollment":186},{"nctId":"NCT05929885","phase":"PHASE2","title":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2023-08-30","conditions":"Metastatic Pancreatic Cancer","enrollment":50},{"nctId":"NCT06494995","phase":"PHASE2","title":"AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-03","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT06157996","phase":"PHASE2","title":"Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":92},{"nctId":"NCT06949098","phase":"PHASE2","title":"Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-05-15","conditions":"Rectal Cancer Stage I","enrollment":60},{"nctId":"NCT06985602","phase":"PHASE2","title":"Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-05-16","conditions":"Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma","enrollment":30},{"nctId":"NCT06848465","phase":"PHASE1","title":"LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis","status":"RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2025-02-28","conditions":"Colorectal Cancer, Liver Metastasis, LDRT","enrollment":9},{"nctId":"NCT06931808","phase":"PHASE4","title":"Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"First Affiliated Hospital of Ningbo University","startDate":"2025-03-01","conditions":"Localized Advanced Rectal Adenocarcinoma","enrollment":20},{"nctId":"NCT06417476","phase":"PHASE2","title":"Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer","status":"RECRUITING","sponsor":"Pei-Rong Ding","startDate":"2022-12-12","conditions":"Rectal Neoplasms","enrollment":66},{"nctId":"NCT05216653","phase":"PHASE2","title":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)","status":"COMPLETED","sponsor":"Sir Run Run Shaw Hospital","startDate":"2022-04-07","conditions":"MSS Locally Advanced Rectal Adenocarcinoma","enrollment":32},{"nctId":"NCT06839560","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-01","conditions":"Brain Metastasis from Advanced HER2-negative Breast Cancer","enrollment":102},{"nctId":"NCT03916510","phase":"PHASE1","title":"Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-07-29","conditions":"Locally Advanced Rectal Cancer","enrollment":12},{"nctId":"NCT06771609","phase":"PHASE2","title":"Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-09-10","conditions":"Advanced Triple-negative Breast Cancer","enrollment":150},{"nctId":"NCT02736448","phase":"PHASE2","title":"177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-05","conditions":"Gastro-entero-pancreatic Neuroendocrine Tumors","enrollment":35},{"nctId":"NCT06758830","phase":"PHASE2, PHASE3","title":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","status":"RECRUITING","sponsor":"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos","startDate":"2025-01-07","conditions":"Rectal Cancer, Total Neoadjuvant Treatment, Neoadjuvant Therapy","enrollment":400},{"nctId":"NCT06425133","phase":"PHASE2","title":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2024-07-19","conditions":"Metastatic Colorectal Cancer","enrollment":174},{"nctId":"NCT04534218","phase":"PHASE2","title":"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2020-10-16","conditions":"Colo-rectal Cancer, Metastatic Cancer","enrollment":49},{"nctId":"NCT05462613","phase":"PHASE2, PHASE3","title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":446},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT06275958","phase":"PHASE3","title":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-07-01","conditions":"Older Patients, Colorectal Cancer, Metastatic Cancer","enrollment":587},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT06561607","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-08","conditions":"Breast Cancer","enrollment":542},{"nctId":"NCT06313567","phase":"PHASE3","title":"Metronomic Capecitabine in Stage III Gastric Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-10","conditions":"Gastric Cancer","enrollment":722},{"nctId":"NCT05420779","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations","status":"RECRUITING","sponsor":"Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.","startDate":"2022-06-30","conditions":"Breast Cancer Metastatic","enrollment":125},{"nctId":"NCT03721744","phase":"PHASE2, PHASE3","title":"A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"1Globe Health Institute LLC","startDate":"2018-10-25","conditions":"Metastatic Pancreatic Cancer","enrollment":336},{"nctId":"NCT06266832","phase":"PHASE2","title":"The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-01-01","conditions":"Rectal Adenocarcinoma","enrollment":30},{"nctId":"NCT06254521","phase":"PHASE2","title":"The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2024-02-22","conditions":"Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":60},{"nctId":"NCT06246461","phase":"NA","title":"The Therapeutic Effect of Different Doses of Capecitabine","status":"COMPLETED","sponsor":"Jingjiang People's Hospital","startDate":"2022-01-01","conditions":"Capecitabine","enrollment":150},{"nctId":"NCT01515787","phase":"PHASE2, PHASE3","title":"PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2012-06-12","conditions":"Colorectal Cancer","enrollment":1194},{"nctId":"NCT04400695","phase":"PHASE3","title":"A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2","status":"UNKNOWN","sponsor":"RemeGen Co., Ltd.","startDate":"2020-09-29","conditions":"Breast Cancer","enrollment":366},{"nctId":"NCT04350021","phase":"","title":"Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2019-03-01","conditions":"Breast Cancer Metastatic, Chemotherapy Effect","enrollment":40},{"nctId":"NCT05578287","phase":"PHASE2","title":"RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-07-18","conditions":"Colorectal Cancer","enrollment":29},{"nctId":"NCT05338866","phase":"","title":"Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2022-01-01","conditions":"Rectal Cancer","enrollment":58},{"nctId":"NCT02024607","phase":"PHASE1, PHASE2","title":"A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-01","conditions":"Advanced Gastrointestinal Cancer","enrollment":495},{"nctId":"NCT06048146","phase":"NA","title":"A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-10-01","conditions":"Lymph Node Metastasis, Cancer of Rectum and Anus, Oxaliplatin","enrollment":180},{"nctId":"NCT06099951","phase":"PHASE2","title":"Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-01","conditions":"Colorectal Cancer","enrollment":53},{"nctId":"NCT02614794","phase":"PHASE2","title":"A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2016-01-28","conditions":"HER2 Positive Breast Cancer","enrollment":612},{"nctId":"NCT05914389","phase":"PHASE2","title":"Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-08","conditions":"Colon Neoplasm","enrollment":100},{"nctId":"NCT05969847","phase":"PHASE2","title":"Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"池畔","startDate":"2023-08-15","conditions":"Rectal Cancer","enrollment":72},{"nctId":"NCT05964543","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors","status":"UNKNOWN","sponsor":"QureBio Ltd.","startDate":"2023-06-21","conditions":"Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":72},{"nctId":"NCT04072107","phase":"PHASE2","title":"EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":110},{"nctId":"NCT05858567","phase":"PHASE2","title":"Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2023-05-11","conditions":"Rectal Cancer","enrollment":30},{"nctId":"NCT02288195","phase":"PHASE3","title":"CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2014-08-13","conditions":"Rectal Neoplasms","enrollment":663},{"nctId":"NCT00258310","phase":"PHASE2","title":"Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2003-12","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT05720559","phase":"PHASE2","title":"Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-01","conditions":"Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer","enrollment":100},{"nctId":"NCT04921995","phase":"PHASE2","title":"Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-04-15","conditions":"Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect","enrollment":40},{"nctId":"NCT04418895","phase":"PHASE2","title":"Neoadjuvant Therapy for Localized Rectal Adenocarcinoma","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-08-13","conditions":"Rectal Adenocarcinoma","enrollment":""},{"nctId":"NCT01302613","phase":"PHASE1, PHASE2","title":"Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-03","conditions":"Stage II Rectal Cancer, Stage III Rectal Cancer","enrollment":""},{"nctId":"NCT04425564","phase":"PHASE2","title":"Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2016-01-01","conditions":"Clinical Response, Toxicity, Survival","enrollment":70},{"nctId":"NCT00081289","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2004-03","conditions":"Colorectal Cancer","enrollment":146},{"nctId":"NCT00727441","phase":"PHASE2","title":"Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-07-02","conditions":"Pancreatic Cancer","enrollment":87},{"nctId":"NCT02280694","phase":"PHASE2","title":"Low Dose Metronomic Poly-chemotherapy for Metastatic CRC","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2015-01","conditions":"Colorectal Cancer","enrollment":45},{"nctId":"NCT03634202","phase":"NA","title":"Study of Radiation Therapy in Combination With Xeloda, for Initially Metastatic, Low and Middle Rectal Cancer","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2015-05-05","conditions":"Rectal Cancer, Metastasis, Radiotherapy","enrollment":9},{"nctId":"NCT03821454","phase":"NA","title":"Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-02-01","conditions":"Breast Cancer","enrollment":50},{"nctId":"NCT01588990","phase":"PHASE4","title":"A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06-26","conditions":"Colorectal Neoplasms","enrollment":128},{"nctId":"NCT00613080","phase":"PHASE2","title":"Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-04","conditions":"Colorectal Cancer","enrollment":79},{"nctId":"NCT01921751","phase":"PHASE2","title":"High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"Radiation Therapy Oncology Group","startDate":"2013-08","conditions":"Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer","enrollment":20},{"nctId":"NCT03507465","phase":"PHASE2, PHASE3","title":"Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-11-29","conditions":"Breast Cancer","enrollment":290},{"nctId":"NCT00478686","phase":"","title":"Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-05-23","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT01589159","phase":"PHASE2","title":"A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes","status":"COMPLETED","sponsor":"Tao OUYANG","startDate":"2013-01","conditions":"Metastatic Breast Cancer","enrollment":54},{"nctId":"NCT02316535","phase":"PHASE3","title":"Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal Cancer","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2014-11","conditions":"Colorectal Neoplasms","enrollment":710},{"nctId":"NCT02829008","phase":"PHASE2","title":"Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-04","conditions":"Metastatic Breast Cancer","enrollment":120},{"nctId":"NCT00009737","phase":"PHASE3","title":"A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1998-11","conditions":"Colorectal Cancer","enrollment":1987},{"nctId":"NCT00869258","phase":"PHASE2","title":"Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar","status":"COMPLETED","sponsor":"Columbia University","startDate":"2005-06","conditions":"Pancreatic Cancer Stage IVA","enrollment":32},{"nctId":"NCT01668680","phase":"PHASE2","title":"Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma","status":"TERMINATED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-09","conditions":"Colorectal Cancer Metastatic","enrollment":80},{"nctId":"NCT01067989","phase":"PHASE2","title":"Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer","status":"TERMINATED","sponsor":"HaEmek Medical Center, Israel","startDate":"2010-03","conditions":"Chemotherapy, Breast Cancer, Metastatic","enrollment":22},{"nctId":"NCT00718354","phase":"PHASE3","title":"Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT","status":"COMPLETED","sponsor":"Thrombosis Research Institute","startDate":"2008-07","conditions":"Gastric Cancer, Gastroesophageal Cancer","enrollment":740},{"nctId":"NCT01229813","phase":"PHASE3","title":"Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2010-10","conditions":"Colorectal Cancer","enrollment":233},{"nctId":"NCT00675012","phase":"PHASE2","title":"NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AGC Biologics S.p.A.","startDate":"2007-12","conditions":"Colon Cancer","enrollment":24},{"nctId":"NCT00095641","phase":"PHASE2","title":"S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"","conditions":"Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx","enrollment":""},{"nctId":"NCT01526512","phase":"PHASE2","title":"Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2011-12","conditions":"Breast Cancer","enrollment":72},{"nctId":"NCT00118300","phase":"PHASE1","title":"Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-04","conditions":"Cervical Cancer, Endometrial Cancer, Ovarian Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Xeloda"],"phase":"phase_3","status":"active","brandName":"low dose capecitabine","genericName":"low dose capecitabine","companyName":"Lund University Hospital","companyId":"lund-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. Used for Adjuvant treatment of Dukes' C and D colon cancer, Monotherapy for treatment of advanced colorectal cancer, Adjuvant treatment of stage III (Dukes' C) colon cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}